Key Points
- CFO Anthony Bergmann sold 25,000 shares on March 31 at an average price of $30.13 for a total of $753,250, leaving him with 8,223 shares — a 75.25% reduction in his holding.
- Capricor's stock is trading higher (opened at $32.11) with a market cap of about $1.85 billion, and analysts hold a consensus "Moderate Buy" rating with an average price target of $46.09 amid several bullish price targets (up to $62) and a few sell ratings.
Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) CFO Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $30.13, for a total transaction of $753,250.00. Following the completion of the sale, the chief financial officer directly owned 8,223 shares in the company, valued at approximately $247,758.99. The trade was a 75.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Capricor Therapeutics Trading Up 6.6%
NASDAQ CAPR opened at $32.11 on Friday. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of -14.21 and a beta of 0.48. The business's 50 day moving average is $27.20 and its two-hundred day moving average is $18.83. Capricor Therapeutics, Inc. has a 12-month low of $4.30 and a 12-month high of $40.37.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.11). Equities analysts forecast that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on CAPR. Cantor Fitzgerald set a $62.00 price objective on Capricor Therapeutics and gave the stock an "overweight" rating in a report on Friday, March 13th. Maxim Group increased their target price on Capricor Therapeutics from $25.00 to $50.00 and gave the stock a "buy" rating in a research report on Thursday, December 4th. Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, January 11th. Piper Sandler restated an "overweight" rating and issued a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Capricor Therapeutics in a research note on Monday, December 29th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $46.09.
Read Our Latest Report on Capricor Therapeutics
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. Farther Finance Advisors LLC acquired a new position in Capricor Therapeutics during the third quarter valued at approximately $28,000. Parkside Financial Bank & Trust acquired a new stake in shares of Capricor Therapeutics in the third quarter worth $36,000. Russell Investments Group Ltd. increased its position in shares of Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company's stock worth $37,000 after acquiring an additional 2,786 shares in the last quarter. ACT Capital Management LLC purchased a new position in shares of Capricor Therapeutics in the 4th quarter valued at $43,000. Finally, GoalVest Advisory LLC purchased a new position in shares of Capricor Therapeutics in the 4th quarter valued at $59,000. Hedge funds and other institutional investors own 21.68% of the company's stock.
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.
The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
